The FDA has granted AbbVie's VENCLEXTA combined with azacitidine breakthrough therapy status for adult patients with myelodysplastic syndrome. Breakthrough therapy status is intended to accelerate the development and review of drugs to treat a serious disease and is granted when preliminary clinical data indicate that the investigational therapy can demonstrate a significant improvement over existing therapies.